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reamble
primary challenge in the development of clinical practice
idelines is keeping pace with the stream of new data on
hich recommendations are based. In an effort to respond
omptly to new evidence, the American College of Cardi-
ogy Foundation/American Heart Association (ACCF/AHA)
ask Force on Practice Guidelines has created a “focused
date” process to revise the existing guideline recommen-
tions that are affected by the evolving data or opinion.
efore the initiation of this focused approach, periodic
dates and revisions of existing guidelines required up to 3
ars to complete. Now, however, new evidence will be
viewed in an ongoing fashion to more efficiently respond to
portant science and treatment trends that could have a
ajor impact on patient outcomes and quality of care.
vidence will be reviewed at least twice a year, and updates
ill be initiated on an as-needed basis and completed as
ickly as possible while maintaining the rigorous method-
ogy that the ACCF and AHA have developed during their
rtnership of more than 20 years. arThese updated guideline recommendations reflect a con-
nsus of expert opinion after a thorough review primarily of
te-breaking clinical trials identified through a broad-based
tting process as being important to the relevant patient
pulation, as well as other new data deemed to have an
pact on patient care (see Section 1.1, Methodology and
vidence Review, for details). This focused update is not
tended to represent an update based on a full literature
view from the date of the previous guideline publication.
ecific criteria/considerations for inclusion of new data
clude the following:
publication in a peer-reviewed journal;
large, randomized, placebo-controlled trial(s);
nonrandomized data deemed important on the basis of
results affecting current safety and efficacy assumptions;
strength/weakness of research methodology and findings;
likelihood of additional studies influencing current findings;
impact on current and/or likelihood of need to develop new
performance measure(s);
request(s) and requirement(s) for review and update from
the practice community, key stakeholders, and other
sources free of relationships with industry or other poten-
tial bias;
number of previous trials showing consistent results; and
need for consistency with a new guideline or guideline
revisions.
In analyzing the data and developing updated recommen-
tions and supporting text, the focused update writing group
ed evidence-based methodologies developed by the ACCF/
HA Task Force on Practice Guidelines that are described
sewhere (1). The Task Force on Practice Guidelines makes
ery effort to avoid actual, potential, or perceived conflicts
interest that may arise as a result of industry relationships
personal interests among the writing group. Specifically,
l members of the writing group, as well as peer reviewers of
e document, are asked to disclose ALL relevant relation-
ips and those existing 12 months before initiation of the
riting effort. In response to implementation of a new
lationship with industry and other entities (RWI) policy
proved by the ACC and AHA, it is also required that the
riting group chair plus a majority of the writing group
0%) have no relevant RWI. All guideline recommendations
quire a confidential vote by the writing group members
fore and after external review of the document and must be
proved by a consensus of the members voting. Members
ho were recused from voting are noted on the title page of
is document and in Appendix 1. Members must recuse
emselves from voting on any recommendations to which
eir RWI apply. Any writing group member who develops a
w RWI during his or her tenure is required to notify
ideline staff in writing. These statements are reviewed by
e Task Force on Practice Guidelines and all members
ring each conference call and/or meeting of the writing
oup and are updated as changes occur. For detailed infor-
ation about guideline policies and procedures, please refer
the ACCF/AHA methodology and policies manual (1).
uthors’ and peer reviewers’ RWI pertinent to this guideline
e disclosed in Appendixes 1 and 2, respectively. Addition-
al
be
R
a
A
w
G
am
in
lis
w
A
vo
cu
as
cl
ab
si
w
re
st
gu
or
re
Fo
ab
cl
us
ar
ex
by
cl
sp
th
L
sc
L
al
of
ce
A
re
is
to
co
ge
at
an
ul
ic
A
st
N
im
on
ta
in
he
in
di
or
m
ul
be
th
ci
be
qu
pr
re
B
ad
he
pa
an
re
m
th
da
ar
re
a
re
ev
gu
co
fo
fo
C
up
A
an
si
1
1
L
sc
of
th
w
G
ke
ba
da
en
20
225JACC Vol. 57, No. 2, 2011 Wann et al.
January 11, 2011:223–42 Guideline Focused Update: Atrial Fibrillationly, to ensure complete transparency, writing group mem-
rs’ comprehensive disclosure information—including
WI not pertinent to this document—are available online as
data supplement. Disclosure information for the ACCF/
HA Task Force on Practice Guidelines is available online at
ww.cardiosource.org/ACC/About-ACC/Leadership/
uidelines-and-Documents-Task-Forces.aspx and at www.
ericanheart.org/presenter.html?identifier3039684. Writ-
g committee members who chose not to participate are not
ted as authors of this focused update. The work of the
riting group was supported exclusively by the ACCF and
HA without commercial support. Writing group members
lunteered their time for this effort.
The committee reviewed and ranked evidence supporting
rrent recommendations, with the weight of evidence ranked
Level A if the data were derived from multiple randomized
inical trials or meta-analyses. The committee ranked avail-
le evidence as Level B when data were derived from a
ngle randomized trial or nonrandomized studies. Evidence
as ranked as Level C when the primary source of the
commendation was consensus opinion of experts, case
udies, or standard of care. In the narrative portions of these
idelines, evidence is generally presented in chronological
der of development. Studies are identified as observational,
trospective, prospective, or randomized where appropriate.
r certain conditions for which inadequate data are avail-
le, recommendations are based on expert consensus and
inical experience and ranked as Level C. An example is the
e of penicillin for pneumococcal pneumonia, where there
e no randomized trials and treatment is based on clinical
perience. When recommendations at Level C are supported
historical clinical data, appropriate references (including
inical reviews) are cited if available. For issues where
arse data are available, a survey of current practice among
e clinicians on the writing committee was the basis for
evel C recommendations and no references are cited. The
hema for Classification of Recommendations (COR) and
evel of Evidence (LOE) is summarized in Table 1, which
so illustrates how the grading system provides an estimate
the size of the treatment effect and an estimate of the
rtainty of the treatment effect. A new addition to the
CCF/AHA methodology is a separation of the Class III
commendations to delineate whether the recommendation
determined to be of “no benefit” or associated with “harm”
the patient. In addition, in view of the increasing number of
mparative effectiveness studies, comparator verbs and sug-
sted phrases for writing recommendations for the compar-
ive effectiveness of one treatment/strategy with respect to
other for COR I and IIa, LOE A or B only have been added.
The ACCF/AHA practice guidelines address patient pop-
ations (and healthcare providers) residing in North Amer-
a. As such, drugs that are not currently available in North
merica are discussed in the text without a specific COR. For
udies performed in large numbers of subjects outside of
orth America, each writing group reviews the potential
pact of different practice patterns and patient populations
the treatment effect and the relevance to the ACCF/AHA
rget population to determine whether the findings should
form a specific recommendation. FiThe ACCF/AHA practice guidelines are intended to assist
althcare providers in clinical decision making by describ-
g a range of generally acceptable approaches for the
agnosis, management, and prevention of specific diseases
conditions. The guidelines attempt to define practices that
eet the needs of most patients in most circumstances. The
timate judgment regarding care of a particular patient must
made by the healthcare provider and patient in light of all
e circumstances presented by that patient. Thus, there are
rcumstances in which deviations from these guidelines may
appropriate. Clinical decision making should consider the
ality and availability of expertise in the area where care is
ovided.
Prescribed courses of treatment in accordance with these
commendations are effective only if they are followed.
ecause lack of patient understanding and adherence may
versely affect treatment outcomes, physicians and other
althcare providers should make every effort to engage the
tient’s active participation in prescribed medical regimens
d lifestyles. When these guidelines are used as the basis for
gulatory or payer decisions, the goal should be improve-
ent in quality of care aligned with the patient’s best interest.
With the exception of the recommendations presented here,
e full-text guideline remains current. Only the recommen-
tions from the affected section(s) of the full-text guideline
e included in this focused update. For easy reference, all
commendations from any section of a guideline affected by
change are presented with notation as to whether they
main current, are new, or have been modified. When
idence affects recommendations in more than 1 set of
idelines, those guidelines are updated concurrently.
The recommendations in this focused update will be
nsidered current until they are superseded by another
cused update or the full-text guidelines are revised. This
cused update is published in the Journal of the American
ollege of Cardiology, Circulation, and HeartRhythm as an
date to the full-text guideline (2), and it is available on the
CC (www.cardiosource.org), AHA (my.americanheart.org),
d Heart Rhythm Society (hrsonline.org) World Wide Web
tes.
Alice K. Jacobs, MD, FACC, FAHA
Chair, ACCF/AHA Task Force on Practice Guidelines
. Introduction
.1. Methodology and Evidence Review
ate-breaking clinical trials presented at the 2009 annual
ientific meetings of the ACC, AHA, and European Society
Cardiology (ESC), as well as selected other data reported
rough April 2010, were reviewed by the standing guideline
riting committee along with the Task Force on Practice
uidelines and other experts to identify those trials and other
y data that may impact guideline recommendations. On the
sis of the criteria/considerations noted above, recent trial
ta and other clinical information were considered important
ough to prompt a focused update of the ACC/AHA/ESC
06 Guidelines for the Management of Patients with Atrial
brillation (2).
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henever deemed appropriate or when published in the
ticle, data from the clinical trial will be used to calculate the
solute risk difference (ARD) and number needed to treat
NT) or harm (NNH); data related to the relative treatment
fects will also be provided, such as odds ratio (OR), relative
sk (RR), hazard ratio (HR), or incidence rate ratio (IRR)
ong with confidence interval (CI) when available.
Consult the full-text version or executive summary of the
CC/AHA/ESC 2006 Guidelines for the Management of
tients with Atrial Fibrillation (2) for policy on clinical areas
t covered by the focused update. The individual recom-
endations in this focused update will be incorporated into
ble 1. Applying Classification of Recommendation and Level o
*Data available from clinical trials or registries about the usefulness/efficacy i
yocardial infarction, history of heart failure, and prior aspirin use. A recommend
any important clinical questions addressed in the guidelines do not lend them
a very clear clinical consensus that a particular test or therapy is useful or
†For comparative effectiveness recommendations (Class I and IIa; Level of Evi
ect comparisons of the treatments or strategies being evaluated.ture revisions and/or updates of the full-text guideline. So.2. Organization of the Writing Committee
r this focused update, all members of the 2006 Atrial
brillation Writing Committee were invited to participate;
ose who agreed (referred to as the 2011 Focused Update
riting Group) were required to disclose all RWI relevant to
e data under consideration. The Heart Rhythm Society was
vited to be a partner on this update and provided 3
presentatives.
.3. Document Review and Approval
his document was reviewed by 2 official reviewers each
minated by the ACCF, the AHA, the Heart Rhythm
nce
nt subpopulations, such as gender, age, history of diabetes, history of prior
th Level of Evidence B or C does not imply that the recommendation is weak.
o clinical trials. Even though randomized trials are not available, there may
.
and B only), studies that support the use of comparator verbs should involvef Evide
n differe
ation wi
selves t
effective
dence Aciety, and 25 individual content reviewers (including
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trial Fibrillation Performance Measures Committee, and the
trial Fibrillation Data Standards Committee). All reviewer
WI information was collected and distributed to the writing
mmittee and is published in this report (Appendix 2).
This document was approved for publication by the gov-
ning bodies of the ACCF, AHA, and Heart Rhythm Society.
. Management
his guideline update focuses on several areas in which new
ta on management of patients with atrial fibrillation (AF)
ve become available, including a) recommendations for
rict versus lenient heart rate control, b) combined use of
tiplatelet and anticoagulant therapy, and c) use of drone-
rone. Recommendations are not made for use of dabigat-
n, a new antithrombotic agent which was not approved by
e U.S. Food and Drug Administration (FDA) at the time of
ganizational approval of this document, or for the Watch-
an device for occlusion of the left atrial appendage which is
vestigational pending FDA approval.
1.3. Rate Control During Atrial Fibrillation
RITERIA FOR RATE CONTROL. In patients with AF, the
ntricular rate may accelerate excessively during exercise
en when it is well controlled at rest (Table 2). Rate
duction, allowing adequate time for ventricular filling and
oiding rate-related ischemia, may result in improved he-
odynamics. Therefore, evaluating the heart rate response to
bmaximal or maximal exercise or to monitor the rate over
extended period (e.g., by 24-hour Holter recording) may
an option. In addition, rate variability during AF provides
formation about the status of the autonomic nervous system
at may have independent prognostic implications (4–7).
rameters for optimal rate control in AF remain controver-
al. The definition of adequate rate control has been based
imarily on short-term hemodynamic benefits and has not
en well studied with respect to regularity or irregularity of
e ventricular response to AF, quality of life, symptoms, or
velopment of cardiomyopathy. No standard method for
sessment of heart rate control has been established to guide
anagement of patients with AF. Criteria for rate control
ble 2. Recommendation for Rate Control During
rial Fibrillation
11 Focused Update Recommendation Comments
ass III–No Benefit
Treatment to achieve strict rate control of heart
rate (80 bpm at rest or 110 bpm during a
6-minute walk) is not beneficial compared to
achieving a resting heart rate 110 bpm in
patients with persistent AF who have stable
ventricular function (left ventricular ejection
fraction 0.40) and no or acceptable symptoms
related to the arrhythmia, though uncontrolled
tachycardia may over time be associated with a
reversible decline in ventricular performance (3).
(Level of Evidence: B)
New recommendationry with patient age but usually involve achieving ventric- coar rates between 60 and 80 bpm at rest and between 90 and
5 bpm during moderate exercise. For the AFFIRM (Atrial
brillation Follow-up Investigation of Rhythm Management)
udy, adequate control was defined as an average heart rate
up to 80 bpm at rest and either an average rate of up to 100
m over at least 18 hours of ambulatory Holter monitoring
ith no rate greater than 100% of the maximum age-adjusted
edicted exercise heart rate or a maximum heart rate of 110
m during a 6-minute walk test (8).
The potential benefits of strict (resting heart rate80 bpm,
art rate110 bpm during moderate exercise) versus lenient
esting heart rate 110 bpm) rate control were addressed in
e RACE II (Rate Control Efficacy in Permanent Atrial
brillation) trial of 614 patients with permanent AF (3). AF
as treated with a variety of atrioventricular (AV) nodal
ocking agents to control heart rate (3). Primary endpoints
ere death from cardiovascular causes, hospitalization for
art failure, stroke, systemic embolism, bleeding, and life-
reatening arrhythmias. The 3-year estimated cumulative
cidence of the primary outcome was 12.9% in the lenient-
ntrol group and 14.9% in the strict-control group (Appen-
x 3), with an absolute difference between lenient control
d strict control of2.0 percentage points (90% CI:7.6 to
5; p0.001) and HR of 0.84 (90% CI: 0.58 to 1.21;
0.001 for the prespecified noninferiority margin). Symp-
ms were also similar in both groups. All patients included in
e study were ambulatory and relatively young (mean age,
years), predominantly male, and may have been healthier
d less symptomatic than many patients encountered in
inical practice. Long-term effects of a more rapid heart rate
sponse to AF on ventricular function were not studied. If a
nient rate control strategy is chosen for patients with persistent
F who have stable ventricular function (left ventricular [LV]
ection fraction0.40) and or no acceptable symptoms related
AF, LV function should be monitored.
The RACE II study reported only a total of 81 composite
ents in 614 patients and was not adequately powered to
ake conclusive comments on whether there were or were
t clinically relevant differences in clinical outcomes be-
een strict- and lenient-rate control (3). Nevertheless, strict
rgeting of treatment to achieve an arbitrary heart rate seems
necessary. The RACE II study shows that lenient-rate
ntrol 110 bpm is not inferior to strict-rate control 80
m. As lenient-rate control is generally more convenient,
quiring fewer outpatient visits and examinations, lenient-
te control may be adopted as a reasonable strategy in
tients with permanent AF.
The Atrial Fibrillation and Congestive Heart Failure Trial
mpared the benefits of rhythm control with rate control in
randomized, multicenter trial of 1,376 patients with AF and
ngestive heart failure (9). AF was defined as 1 episode of
F lasting at least 6 hours or requiring cardioversion within
e preceding 6 months or an episode lasting for at least 10
inutes within the previous 6 months and previous cardio-
rsion. Congestive heart failure was defined as an ejection
action of 35% and symptomatic New York Heart Asso-
ation (NYHA) class II or IV heart failure within the
evious 6 months, or an ejection fraction of 25%. Rhythm
ntrol included cardioversion and antiarrhythmic therapy,
pr
an
co
di

fo
ca
ei
w
0.
in
st
w
co
w
a
sy
8.
W
st
w
A
m
A
A
R
ag
pa
Ir
co
th
pa
ou
sy
va
re
an
5.
47
2
w
th
2.
2.
95
ca
do
an
T
bl
an
O
cl
pa
at
Pa
ad
va
ab
(A
an
pa
T
no
va
ev
cl
A
0.
pr
cl
pl
pl
p
(0
pe
bl
do
pl
p
w
do
es
cl
(t
an
co
pr
is
m
en
ad
8.
A
A
th
in
20
Ta
An
20
Cl
1.
228 Wann et al. JACC Vol. 57, No. 2, 2011
Guideline Focused Update: Atrial Fibrillation January 11, 2011:223–42imarily using amiodarone, repeat cardioversion if needed,
d possible referral for nonpharmacologic therapy. Rate
ntrol was achieved primarily using beta blockers with
gitalis to achieve a target heart rate of 80 bpm at rest or
110 bpm during a 6-minute walk test. No difference was
und in the primary endpoint of death from cardiovascular
uses with a mean follow-up of 37 months. One hundred
ghty-two (27%) in the rhythm-control group died compared
ith 175 (25%) in the rate-control group (HR: 1.06; 95% CI:
86 to 1.30; p0.59) by log rank test. Secondary outcomes,
cluding death from any cause, worsening heart failure,
roke, and composite and death from cardiovascular causes,
ere also similar in both groups. Patients treated with rhythm
ntrol were more likely to be hospitalized than those treated
ith rate control (9). This trial showed no benefit for use of
routine strategy of rhythm control in patients with AF and
stolic heart failure compared with a strategy of rate control.
1.4.2.4. RECOMMENDATIONFORCOMBININGANTICOAGULANT
ITH ANTIPLATELET THERAPY (NEW SECTION). Multiple
udies have demonstrated that oral anticoagulation with
arfarin is effective for prevention of thromboembolism in
F patients (Table 3) (2,11–16). Aspirin (ASA) offers only
odest protection against stroke for AF patients (13,17–23).
djusted-dose oral anticoagulation is more efficacious than
SA for prevention of stroke in patients with AF (2,24).
ecent studies have assessed the thienopyridine antiplatelet
ent clopidogrel with ASA for stroke prevention in AF
tients (10,25).
The ACTIVE-W (Atrial Fibrillation Clopidogrel Trial with
besartan for Prevention of Vascular Events) trial (25)
mpared clopidogrel plus ASA with oral anticoagulation
erapy with warfarin for prevention of vascular events in AF
tients with an average of 2 stroke risk factors. The primary
tcome was first occurrence of stroke, noncentral nervous
stem systemic embolism, myocardial infarction (MI), or
scular death. There were 165 primary events in patients
ceiving oral anticoagulation therapy (annual risk: 3.93%)
d 234 in those receiving clopidogrel plus ASA (annual risk:
60%; RR: 1.44 [95% CI: 1.18 to 1.76; p0.0003; NNT:
]). Although rates of hemorrhage were similar between the
groups, significantly greater minor and total bleeds occurred
ith clopidogrel and ASA than with oral anticoagulation
erapy. Major hemorrhages (severe and fatal) occurred in
ble 3. Recommendation for Combining Anticoagulant With
tiplatelet Therapy
11 Focused Update Recommendation Comments
ass IIb
The addition of clopidogrel to aspirin (ASA)
to reduce the risk of major vascular
events, including stroke, might be
considered in patients with AF in whom
oral anticoagulation with warfarin is
considered unsuitable due to patient
preference or the physician’s assessment
of the patient’s ability to safely sustain
anticoagulation (10). (Level of Evidence: B)
New recommendation42% of patients treated with clopidogrel plus ASA and in ab21% of those treated with oral anticoagulation (RR: 1.10;
% CI: 0.83 to 1.45; p0.53). Total hemorrhagic compli-
tions occurred in 15.40% of patients treated with clopi-
grel plus ASA and in 13.21% of those treated with oral
ticoagulation (RR: 1.21; 95% CI: 1.08 to 1.35; p0.001).
he total adverse outcome (primary outcome and major
eeds) was 316 in clopidogrel and ASA and 229 in oral
ticoagulation (RR: 1.41; 95% CI: 1.19 to 1.67; p0.001).
ral anticoagulation therapy with warfarin proved superior to
opidogrel plus ASA for prevention of vascular events in AF
tients. Treatment with clopidogrel plus ASA was associ-
ed with bleeding risk similar to treatment with warfarin.
The ACTIVE-A (Effect of Clopidogrel Added to Aspirin in
tients with Atrial Fibrillation) trial assessed whether the
dition of clopidogrel to ASA would reduce the risk of
scular events in AF patients who were considered unsuit-
le for therapy with oral anticoagulation with warfarin (10)
ppendix 3). Patients were deemed “unsuitable” for oral
ticoagulation due to a specific risk of bleeding (22.9%),
tient preference (26%), or physician preference (49.7%).
he primary outcome was the composite of stroke, MI,
ncentral nervous system systemic embolism, or death from
scular causes. At 3.6 years of follow-up, major vascular
ents had occurred in 832 patients receiving ASA plus
opidogrel (6.8% per year) and in 924 patients receiving
SA plus placebo (7.6% per year) (RR with clopidogrel:
89; 95% CI: 0.81 to 0.98; p0.01). The difference was
imarily due to a reduction in the rate of stroke with
opidogrel. Stroke occurred in 296 patients receiving ASA
us clopidogrel (2.4% per year) and in 408 patients receiving
acebo (3.3% per year; RR: 0.72; 95% CI: 0.62 to 0.83;
0.001). MI occurred in 90 patients receiving clopidogrel
.7% per year) and in 115 patients receiving placebo (0.9%
r year) (RR: 0.78; 95% CI: 0.59 to 1.03; p0.08). Major
eeding occurred in 251 patients receiving ASA plus clopi-
grel (2.0% per year) and in 162 patients receiving ASA
us placebo (1.3% per year; RR: 1.57; 95% CI: 1.29 to 1.92;
0.001). In AF patients for whom oral anticoagulation with
arfarin was considered unsuitable, the addition of clopi-
grel to ASA reduced the risk of major vascular events,
pecially stroke, and increased the risk of major hemorrhage.
The combined use of dual-antiplatelet therapy with both
opidogrel and ASA plus anticoagulation with warfarin
riple therapy) has been suggested as a strategy for treatment
d prevention of complications of 2 or more coexisting
nditions such as AF, mechanical valve prosthesis, or the
esence of a drug-eluting coronary stent (26). This strategy
associated with an increase in bleeding complications that
ight range from mild or moderate to severe or life threat-
ing. No prospective randomized trials have been reported
dressing this important clinical issue.
1.4.2.5. EMERGINGAND INVESTIGATIONALANTITHROMBOTIC
GENTS. The RE-LY (Randomized Evaluation of Long-Term
nticoagulation Therapy) trial of dabigatran (27), a prodrug
at is rapidly converted to an active direct thrombin inhibitor
dependent of the cytochrome P-450, was reviewed by the
11 Focused Update Writing Group, but recommendations
out its use are not included in this focused update because
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e time of organizational approval.
1.4.3. NONPHARMACOLOGIC APPROACHES TO PREVENTION OF
ROMBOEMBOLISM
he 2011 Focused Update Writing Group considered the
atchman device for atrial appendage closure in its deliber-
ions in anticipation of FDA approval of this device (28).
ecause the FDA has not approved clinical use of the
atchman device pending the results of additional ongoing
ials, the writing group’s deliberations and recommendations
garding the Watchman device are not included in the final
rsion of this focused update. A future guideline writing
mmittee will address this and other evolving areas in the
anagement of AF.
1.8.3. RECOMMENDATIONS FOR DRONEDARONE FOR THE PREVENTION OF
CURRENT ATRIAL FIBRILLATION (NEW SECTION)
ronedarone is similar to amiodarone but lacks an iodine
oiety. Its multiple electrophysiologic actions include sym-
tholytic effects as well as inhibition of the L-type calcium
rrent, the inward sodium current, and multiple potassium
rrents (Table 4) (31). Two randomized trials (EURIDIS
uropean Trial In Atrial Fibrillation or Flutter Patients
eceiving Dronedarone for the Maintenance of Sinus
hythm] and ADONIS [American-Australian-African Trial
ith Dronedarone in Atrial Fibrillation or Flutter Patients for
e Maintenance of Sinus Rhythm]) found that dronedarone
olongs the time to recurrence of AF (Appendix 3) (32,33).
patients with persistent AF, DAFNE (Dronedarone Atrial
brillatioN study after Electrical Cardioversion) showed that
ministration of dronedarone converted only 5.8% to sinus
ythm (3.1% converted with placebo) and did not improve
e acute success of electrical cardioversion (33). Dronedar-
e slows the ventricular rate in AF by an average of 11 to 13
m (33,34). Incidence of spontaneous conversion to sinus
ythm was dose related (i.e., 800, 1,200, and 1,600 mg). The
nversion ratio was 5.8% (800 mg), 8.2% (1,200 mg), and
.2% (1,600 mg), but the incidence of successful electrical
ble 4. Recommendations for Use of Dronedarone in
rial Fibrillation
11 Focused Update Recommendations Comments
ass IIa
Dronedarone is reasonable to decrease the need
for hospitalization for cardiovascular events in
patients with paroxysmal AF or after conversion
of persistent AF. Dronedarone can be initiated
during outpatient therapy (29). (Level of
Evidence: B)
New recommendation
ass III–Harm
Dronedarone should not be administered to
patients with class IV heart failure or patients
who have had an episode of decompensated
heart failure in the past 4 weeks, especially if
they have depressed left ventricular function (left
ventricular ejection fraction 35%) (30). (Level
of Evidence: B)
New recommendationrdioversion was not statistically different between groups fa00 mg77.3%; 1,200 mg87.9%; and 1,600 mg76.6%
rsus 73.0% in the placebo group) (33).
Dronedarone is generally less efficacious than amiodarone
5). The DIONYSOS (Efficacy & Safety of Dronedarone
ersus Amiodarone for the Maintenance of Sinus Rhythm in
tients With Persistent Atrial Fibrillation) study was a
ort-term, randomized, double-blind, parallel-group study
at evaluated the efficacy and safety of dronedarone versus
iodarone (36). In patients with persistent AF, dronedarone
as less effective than amiodarone in decreasing AF recur-
nce in 504 patients with persistent AF randomized to
eatment with either dronedarone or amiodarone, but it was
tter tolerated (Appendix 3). The primary composite end-
int was recurrence of AF (including unsuccessful electrical
rdioversion, no spontaneous conversion, and no electrical
rdioversion) or premature study discontinuation was
hieved in 75.1% of patients taking dronedarone and 58.8%
king amiodarone at 12 months (HR: 1.59; 95% CI: 1.28 to
98; p0.0001). Premature discontinuation of study drug
curred in 10.4% of the dronedarone group and 13.3% of the
iodarone group. Main safety endpoints were observed in
.3% of dronedarone patients versus 44.5% of amiodarone
tients (HR: 0.80; 95% CI: 0.60 to 1.07; p0.129). Fewer
yroid, neurologic, dermatologic, and ocular events occurred
the dronedarone group.
The ATHENA (A placebo-controlled, double-blind, paral-
l arm Trial to assess the efficacy of dronedarone 400 mg bid
r the prevention of cardiovascular Hospitalization or death
om any cause in patiENts with Atrial fibrillation/atrial
tter) trial included patients with paroxysmal or persistent
F or atrial flutter and risk factors for thromboembolism (29)
ppendix 3). Dronedarone reduced the combined endpoint
death and cardiovascular hospitalizations, largely by re-
cing hospitalizations related to AF (and cardiovascular
ath); death from any cause was not reduced (29). Mainte-
nce of sinus rhythm was not a discrete endpoint in this trial.
wer strokes occurred in the dronedarone group, although
is effect was not prespecified and requires confirmation by
her trials (37). The ATHENA trial excluded patients with
compensated heart failure within the previous 4 weeks, or
ith NYHA class IV heart failure. There was no evidence of
adverse effect of dronedarone in patient subgroups with a
story of congestive heart failure or LV ejection fraction
35% (29). Note that evidence of efficacy is based on
duced hospitalization for AF, acute coronary syndrome and
l cause mortality, not maintenance of sinus rhythm.
In a trial of patients with recently decompensated heart
ilure and depressed LV function, ANDROMEDA (Antiar-
ythmic Trial with Dronedarone in Moderate to Severe CHF
valuating Morbidity Decrease), dronedarone increased mor-
lity after a median follow-up of only 2 months; 8.1% in the
onedarone group died and 3.8% in the placebo group died
R: 2.13; 95% CI: 1.07 to 4.25; p0.03) (Appendix 3) (30).
he higher mortality was associated with more progression of
art failure. Therefore, dronedarone should not be adminis-
red to patients with depressed ventricular function and
cent heart failure decompensation or NYHA class IV heart
ilure.
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adycardia and QT prolongation. Torsades de pointes has
en reported (29). Like amiodarone, dronedarone inhibits
nal tubular secretion of creatinine, which can increase
asma creatinine levels. However, there is no reduction in
omerular filtration rate. Dronedarone increases digoxin
vels 1.7- to 2.5-fold (31). Dronedarone is predominantly
etabolized by the liver (CYP3A4) with a half-life of
proximately 19 hours. It should not be administered with
rong inhibitors of CYP3A4 (e.g., ketoconazole and macro-
e antibiotics) because these may potentiate the effects of
onedarone. It can be administered with verapamil or dilti-
em, which are moderate CYP3A4 inhibitors, but low doses
these agents should be used initially and titrated according
response and tolerance (31). Dronedarone does not alter the
ternational normalization ratio when used with warfarin.
he recommended oral dose of dronedarone is 400 mg twice
day with meals. An intravenous form is not available.
.3. Maintenance of Sinus Rhythm
3.1. Recommendations for Therapy
gure 1 incorporates dronedarone into the algorithm previ-
sly recommended for therapy to maintain sinus rhythm in
tients with recurrent paroxysmal or persistent AF (Table 5).
3.1.4. FUTURE DIRECTIONS IN CATHETER-BASED ABLA-
ON THERAPY FOR ATRIAL FIBRILLATION (NEW SECTION)
atheter ablation to maintain sinus rhythm has been reported
trials and meta-analyses including data from more than
900 patients (38–51). Patients undergoing ablation are a
lected population characterized by a predominance of those
ith symptomatic paroxysmal AF that has failed treatment
gure 1. Therapy to maintain sinus rhythm in patients with recurr
tically and not in order of suggested use. The seriousness of he
tients with multiple conditions depends on the most serious con
m Fuster et al. (2) (formerly Figure 15 from 2006 Section 8.3.3).ith one or more antiarrhythmic drugs, with normal size or syildly dilated atria, normal or mildly reduced ventricular
nction, and absence of severe pulmonary disease. Follow-
g ablation, most patients are free of recurrent, paroxysmal
F for 1 year or more.
In the ThermoCool trial, a randomized multicenter study of
7 symptomatic patients with paroxysmal AF who had not
own improvement with at least 1 antiarrhythmic drug,
diofrequency catheter ablation with pulmonary vein isola-
n resulted in significantly fewer episodes of recurrent AF
an did treatment with additional antiarrhythmic drugs (51)
ppendix 3). Quality-of-life and symptom severity scores
ere significantly better after 3 months in the group treated
ith catheter ablation. Major treatment-related adverse events
ere similar between catheter-treated and drug-treated
oups at 30 days. More than 5,000 patients were screened to
cruit these 167 study subjects. Important exclusions in-
uded patients with AF30 days’ duration, ejection fraction
40%, left atrial diameter 5 cm, severe pulmonary disease,
cent MI, coronary artery bypass graft surgery, thromboem-
li, treatment with amiodarone, or previous catheter abla-
ns for AF (51). The average age of patients undergoing
theter ablation was relatively young at 55.7 years (95% CI:
.1 to 57.4), and they had paroxysmal, symptomatic AF for
relatively long time: 5.7 years (95% CI: 4.8 to 6.6). All
lation procedures were performed by highly experienced
erators in high-volume centers. Although the primary
dpoint in all centers was electrical isolation of all pulmo-
ry veins in each patient who underwent AF ablation, other
pects of the ablation procedures were not standardized,
cluding the use of linear lesions. Repeat catheter ablation
ocedures were performed in 12.6% of the ablation group.
ltimately, 34% of ablation patients had recurrence of
oxysmal or persistent atrial fibrillation. Drugs are listed alpha-
ase progresses from left to right, and selection of therapy in
present. LVH indicates left ventricular hypertrophy. Modifiedent par
art dise
ditionmptomatic AF during the 9-month follow-up period, com-
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06 Recommendations 2011 Focused Update Recommendations Comments
ass I
Before initiating antiarrhythmic drug therapy, treatment
of precipitating or reversible causes of AF is
recommended. (Level of Evidence: C)
1. Before initiating antiarrhythmic drug therapy, treatment
of precipitating or reversible causes of AF is
recommended. (Level of Evidence: C)
2006 recommendation remains current.
2. Catheter ablation performed in experienced centers* is
useful in maintaining sinus rhythm in selected patients
with significantly symptomatic, paroxysmal AF who
have failed treatment with an antiarrhythmic drug and
have normal or mildly dilated left atria, normal or
mildly reduced LV function, and no severe pulmonary
disease (38–51). (Level of Evidence: A)
Modified recommendation (class of
recommendation changed from IIa to I,
wording revised, and level of evidence
changed from C to A).
ass IIa
Pharmacological therapy can be useful in patients with
AF to maintain sinus rhythm and prevent tachycardia-
induced cardiomyopathy. (Level of Evidence: C)
1. Pharmacological therapy can be useful in patients with
AF to maintain sinus rhythm and prevent tachycardia-
induced cardiomyopathy. (Level of Evidence: C)
2006 recommendation remains current.
Infrequent, well-tolerated recurrence of AF is
reasonable as a successful outcome of antiarrhythmic
drug therapy. (Level of Evidence: C)
2. Infrequent, well-tolerated recurrence of AF is
reasonable as a successful outcome of antiarrhythmic
drug therapy. (Level of Evidence: C)
2006 recommendation remains current.
Outpatient initiation of antiarrhythmic drug therapy is
reasonable in patients with AF who have no
associated heart disease when the agent is well
tolerated. (Level of Evidence: C)
3. Outpatient initiation of antiarrhythmic drug therapy is
reasonable in patients with AF who have no
associated heart disease when the agent is well
tolerated. (Level of Evidence: C)
2006 recommendation remains current.
In patients with lone AF without structural heart
disease, initiation of propafenone or flecainide can be
beneficial on an outpatient basis in patients with
paroxysmal AF who are in sinus rhythm at the time of
drug initiation. (Level of Evidence: B)
4. In patients with AF without structural or coronary heart
disease, initiation of propafenone or flecainide can be
beneficial on an outpatient basis in patients with
paroxysmal AF who are in sinus rhythm at the time of
drug initiation (52–54). (Level of Evidence: B)
Modified recommendation (wording clarified).
Sotalol can be beneficial in outpatients in sinus rhythm
with little or no heart disease, prone to paroxysmal
AF, if the baseline uncorrected QT interval is less than
460 ms, serum electrolytes are normal, and risk
factors associated with Class III drug–related
proarrhythmia are not present. (Level of Evidence: C)
5. Sotalol can be beneficial in outpatients in sinus
rhythm with little or no heart disease, prone to
paroxysmal AF, if the baseline uncorrected QT interval
is less than 460 ms, serum electrolytes are normal,
and risk factors associated with Class III drug–related
proarrhythmia are not present. (Level of Evidence: C)
2006 recommendation remains current.
6. Catheter ablation is reasonable to treat symptomatic
persistent AF (38,48,55–64). (Level of Evidence: A)
New recommendation
Catheter ablation is a reasonable alternative to
pharmacological therapy to prevent recurrent AF in
symptomatic patients with little or no left atrium
enlargement. (Level of Evidence: C)
Modified recommendation (class of
recommendation changed from IIa to I,
wording revised and level of evidence
changed from C to A).
ass IIb 1. Catheter ablation may be reasonable to treat
symptomatic paroxysmal AF in patients with
significant left atrial dilatation or with significant LV
dysfunction (38,48,55–64). (Level of Evidence: A)
New recommendation
ass III–Harm
Antiarrhythmic therapy with a particular drug is not
recommended for maintenance of sinus rhythm in
patients with AF who have well-defined risk factors for
proarrhythmia with that agent. (Level of Evidence: A)
1. Antiarrhythmic therapy with a particular drug is not
recommended for maintenance of sinus rhythm in
patients with AF who have well-defined risk factors for
proarrhythmia with that agent (65,66). (Level of
Evidence: A)
2006 recommendation remains current.
Pharmacological therapy is not recommended for
maintenance of sinus rhythm in patients with
advanced sinus node disease or AV node dysfunction
unless they have a functioning electronic cardiac
pacemaker. (Level of Evidence: C)
2. Pharmacological therapy is not recommended for
maintenance of sinus rhythm in patients with
advanced sinus node disease or AV node dysfunction
unless they have a functioning electronic cardiac
pacemaker. (Level of Evidence: C)
2006 recommendation remains current.
*Refers to pulmonary vein isolation with catheter ablation. An experienced center is defined as one performing more than 50 AF catheter ablation cases per year
7). Evidence-based technical guidelines including operator training and experience necessary to maximize rates of successful catheter ablation are not available;
ch center should maintain a database detailing procedures; success and complications, engage strategies for continuous quality improvement, and participate in
gistries and other efforts pooling data in order to develop optimal care algorithms (68).
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lected patient population, in patients for whom 1 antiar-
ythmic drug has failed, subsequent antiarrhythmic drug
eatment is likely to fail; such patients may benefit from
theter ablation.
Despite these advances, the long-term efficacy of cath-
er ablation to prevent recurrent AF requires further
udy. Available data demonstrate 1 year or more of
eedom from recurrent AF in most (albeit carefully
lected) patients (69 –71). However, AF can recur without
mptoms and be unrecognized by the patient or physician.
here is uncertainty as to what the risk of recurrence of AF
over the long term, because AF may recur with minimal
mptoms. This distinction has important implications for
e duration of anticoagulation therapy in patients with risk
ctors for stroke associated with AF. In addition, little
formation is yet available about the late success of
lation in patients with heart failure and other advanced
ructural heart disease, who may be less likely to enjoy
eedom from recurrence of AF (72).
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Appendix 3. Summary Table
Study Aim of Study Study Size Patient Population/Inclusion and Exclusion Criteria Endpoint(s) Statistical Analysis Reported CI and/or p Values OR/HR/RR/Other Study Conclusion
ACTIVE A,
Connolly et al.
(10)
To investigate whether
the addition of
clopidogrel to ASA would
reduce risk of vascular
events in patients with
AF considered unsuitable
for oral anticoagulation
with warfarin.
7,554 Inclusion criteria: AF at enrollment or at least 2 episodes
of intermittent AF in previous 6 mo and at least 1 of the
following risk factors for stroke: age 75 y; systemic
HTN during treatment; previous stroke, TIA, or non-CNS
systemic embolism; LVEF 45%; PVD; or age 55–74 y
and DM or CAD.
Exclusion criteria: Requirement of vitamin K antagonist
or clopidogrel or the presence of any of the following
risk factors for hemorrhage: documented peptic ulcer
disease within previous 6 mo, history of intracerebral
hemorrhage, significant thrombocytopenia (platelet count
50109 per liter), or ongoing alcohol abuse.
Primary outcome was composite
of stroke, MI, non-CNS systemic
embolism, or death from vascular
causes.
Major vascular events occurred in 832 patients receiving
ASA plus clopidogrel (6.8% per year) and in 924 patients
receiving ASA plus placebo (7.6% per year).
95% CI: 0.81 to 0.98;
p0.01
RR: 0.89 In AF patients considered
unsuitable for warfarin,
the addition of
clopidogrel to ASA
reduced risk of major
vascular events,
especially stroke, and
increased risk of major
hemorrhage.
Stroke occurred in 296 patients receiving ASA plus
clopidogrel (2.4% per year) and 408 patients receiving
ASA plus placebo (3.3% per year).
95% CI: 0.62 to 0.83;
p0.001
RR: 0.72
MI occurred in 90 patients receiving ASA plus
clopidogrel (0.7% per year) and in 115 receiving ASA
plus placebo (0.9% per year).
95% CI: 0.59 to 1.03;
p0.08
RR: 0.78
Major bleeding occurred in 251 patients receiving ASA
plus clopidogrel (2.0% per year) and in 162 patients
receiving ASA plus placebo (1.3% per year).
95% CI: 1.29 to 1.92;
p0.001
RR: 1.57
ACTIVE W,
Connolly et al.
(25)
To determine if
clopidogrel plus ASA was
noninferior to oral
anticoagulation therapy
for prevention of vascular
events in patients with
AF.
6,706 Inclusion criteria: ECG evidence of AF; age 75 y;
treatment for systemic HTN, previous stroke, TIA, or
non-CNS systemic embolus; LV dysfunction with LVEF
45%; PAD; if age 55–74 y without 1 of the other
inclusion criteria, then DM requiring drug therapy or
previous CAD.
Exclusion criteria: Contraindication for clopidogrel or oral
anticoagulant (ie, prosthetic mechanical heart valve),
documented peptic ulcer disease within previous 6 mo,
previous intracerebral hemorrhage, significant
thrombocytopenia (platelet count 50109 per liter) or
mitral stenosis.
Primary outcome was first
occurrence of stroke, non-CNS
systemic embolism, MI, or
vascular death.
Composite of stroke, non-CNS embolus, MI, vascular
death: 164 events in patients on oral anticoagulation
(annual risk: 3.90%) and 234 events in patients on
clopidogrel plus ASA (annual risk: 5.60%).
95% CI: 1.18 to 1.76;
p0.0003
RR: 1.44 Oral anticoagulation with
warfarin is superior to
clopidogrel plus ASA in
preventing vascular
events, including stroke,
in patients with AF.
Stroke (100 events for clopidogrel plus ASA; 59 events
for oral anticoagulation).
95% CI: 1.24 to 2.37;
p0.001
RR: 1.72
Non-CNS embolism (18 events for clopidogrel plus ASA;
4 for oral anticoagulation).
95% CI: 1.58 to 13.8;
p0.005
RR: 4.66
Patients on oral anticoagulation who already received
this treatment at study entry had a trend toward greater
reduction in vascular events.
95% CI: 1.19 to 1.80;
p0.0005
RR: 1.50
And a lower risk of major bleeding on oral
anticoagulation therapy.
95% CI: 0.94 to 1.79;
p0.11
RR: 1.30
Than patients not on oral anticoagulation therapy at
entry.
95% CI: 0.85 to 1.89;
p0.24
RR: 1.27
ADONIS,
Singh et al.
(32)
To investigate effect of
dronedarone for
maintenance of SR after
electrical, pharmacologic,
or spontaneous
conversion from AF or
atrial flutter.
208 in placebo group
and 417 in
dronedarone group
Inclusion criteria: Either sex, age at least 21 y, and at
least 1 episode of AF (as seen on ECG) in preceding 3
mo and in SR for at least 1 h before randomization.
Exclusion criteria: Patients with permanent AF (ie,
duration of at least 12 mo); women who could become
pregnant and who were not using birth control; patients
who had torsades de pointes; patients with persistent
bradycardia of 50 bpm, PR interval of 0.28 s on
ECG, second-degree (or higher) AVB, and clinically
significant sinus-node disease without an implanted
pacemaker; patients taking Class I or III antiarrhythmic
agents; patients with NYHA class III or IV CHF; and
patients with serum creatinine level 1.7 mg/dL (150
mol/L), severe electrolyte abnormalities, and clinically
significant hepatic, pulmonary, endocrine, or other
disorders associated with AF.
Primary endpoint was time from
randomization to first documented
recurrence of AF. Secondary
endpoints were symptoms and
mean ventricular rate during first
AF recurrence.
Median times from randomization to documented
recurrence of AF were 158 d in dronedarone group and
59 d in placebo group. At 12 mo, 61.1% of patients in
dronedarone group and 72.8% of patients in placebo
group had recurrence of AF.
HR: 0.73 Dronedarone was
significantly more
effective than placebo in
maintaining SR.
(Continued)
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Rhythm Control
versus Rate
Control for
Atrial
Fibrillation and
Heart Failure
(AF and CHF
Investigators)
(9)
To investigate
maintenance of SR
(rhythm control) with
ventricular rate control in
patients with LVEF
35% and symptoms of
CHF and history of AF.
1,376 (682 in
rhythm-control group
and 694 in rate-
control group)
Inclusion criteria: LVEF 35% (measured by nuclear
imaging, echocardiography, or cardiac angiography, with
testing performed 6 mo before enrollment); history of
CHF (defined as symptomatic NYHA class II or IV) within
previous 6 mo, asymptomatic condition that patient had
been hospitalized for HF during previous 6 mo, or LVEF
25%; history of AF (with ECG documentation) defined
as 1 episode lasting for at least 6 h or requiring
cardioversion within previous 6 mo or episode lasting for
at least 10 min within previous 6 mo and previous
electrical cardioversion for AF; and eligibility for long-
term therapy in either of the 2 study groups.
Exclusion criteria: Persistent AF for 12 mo, reversible
cause of AF or HF, decompensated HF within 48 h
before intended randomization, use of antiarrhythmic
drugs for other arrhythmias, second- or third-degree
AVB (bradycardia of 50 bpm), history of long-QT
syndrome, previous ablation of AV node, anticipated
cardiac transplantation within 6 mo, renal failure
requiring dialysis, lack of birth control in women of
childbearing potential, estimated life expectancy 1 y,
and age 18 y.
Primary outcome was time to
death from CV causes.
The primary outcome, death from CV causes, occurred
in 182 patients (27%) in rhythm-control group and 175
patients (25%) in rate-control group.
None of the secondary
outcomes differed
significantly between
treatment groups.
HR: 1.06 The routine strategy of
rhythm control does not
reduce the rate of death
from CV causes
compared with a rate-
control strategy in
patients with AF and
CHF.
95% CI: 0.86 to 1.30;
p0.53
Death from any cause (32% in rhythm-control group and
33% in rate-control group).
95% CI: 0.80 to 1.17;
p0.73
HR: 0.97
Ischemic or hemorrhagic stroke, 3% and 4%,
respectively.
95% CI: 0.40 to 1.35;
p0.32
HR: 0.74
Worsening HF (defined as HF requiring hospitalization,
administration of IV diuretic, or change in treatment
strategy).
95% CI: 0.72 to 1.06;
p0.17
HR: 0.87
Composite outcome of death from CV causes, stroke, or
worsening HF.
95% CI: 0.77 to 1.06;
p0.20
HR: 0.90
AFFIRM,
Olshansky et al.
(8)
To evaluate and compare
several drug classes for
long-term ventricular rate
control.
2,027 Inclusion criteria: (All criteria must have been met.)
Episode of AF documented on ECG or rhythm strip
within last 6 wk, age 65 y or 65 y plus 1 clinical
risk factor for stroke (systemic HTN, DM, CHF, TIA, prior
cerebral vascular accident, left atrium 50 mm on
echocardiogram, fractional shortening 25% on
echocardiogram [unless paced or LBBB present], or
LVEF 40% (on radionuclide ventriculogram, contrast
angiography, or quantitative echocardiography), duration
of AF episodes in last 6 mo must total 6 h unless
electrical and/or pharmacological cardioversion was
performed before 6 h, duration of continuous AF must
be 6 mo unless normal SR can be restored and
maintained for 24 h in opinion of clinical investigator,
patient (based on clinical and laboratory evaluation
before randomization) must be eligible for both
treatment groups based on history, patient must be
eligible for 2 antiarrhythmic drugs (or 2 dose levels of
amiodarone) and 2 rate-controlling drugs.
Exclusion criteria: Not presented based on judgment that
certain therapies are contraindicated or inclusion would
confound the result. Criteria included cardiac, other
medical, and nonmedical.
Overall rate control with various
drugs (average follow-up 3.51.3
y).
Overall rate control was met in 70% of patients given
beta blockers as the first drug (with or without digoxin)
versus 54% with calcium channel blockers (with or
without digoxin) and 58% with digoxin alone.
Multivariate analysis revealed a significant association
between first drug class and several clinical variables,
including gender, history of CAD, pulmonary disease,
CHF, HTN, qualifying episode being first episode of AF,
and baseline heart rate.
Rate control is possible
in the majority of patients
with AF. In the AFFIRM
follow-up study, beta
blockers were most
effective. The authors
noted frequent
medication changes and
drug combinations were
needed.
(Continued)
237
JACC
Vol.57,No.2,2011
W
ann
et
al.
January
11,2011:223–42
Guideline
Focused
Update:
AtrialFibrillation
Appendix 3. Continued
Study Aim of Study Study Size Patient Population/Inclusion and Exclusion Criteria Endpoint(s) Statistical Analysis Reported CI and/or p Values OR/HR/RR/Other Study Conclusion
ANDROMEDA,
Kober et al.
(30)
To evaluate efficacy of
dronedarone in reducing
hospitalization due to
CHF in patients with
symptomatic HF.
627 Inclusion criteria: Patients age 18 y hospitalized with
new or worsening HF and who had at least 1 episode of
SOB on minimal exertion or at rest (NYHA class III or IV)
or paroxysmal nocturnal dyspnea within 1 mo before
admission and wall-motion index of no more than 1.2
(approximating EF of no more than 35%).
Exclusion criteria: Acute MI within 7 d before screening,
heart rate 50 bpm, PR interval 0.28 s, sinoatrial
block or second- or third-degree AVB not treated with
pacemaker, history of torsades de pointes, corrected QT
interval 500 ms, serum potassium level 3.5 mmol/L,
use of Class I or III antiarrhythmic drugs, drugs known
to cause torsades de pointes, or potent inhibitors of
P450 CYP3A4 cytochrome system, other serious
disease, acute myocarditis, constrictive pericarditis,
planned or recent (within preceding month) cardiac
surgery or angioplasty, clinically significant obstructive
heart disease, acute pulmonary edema within 12 h
before randomization, pregnancy or lactation, expected
poor compliance, or participation in another clinical trial
and previous treatment with dronedarone.
The primary endpoint was
composite of death from any
cause or hospitalization for HF.
After inclusion of 627 patients, the trial was prematurely
terminated for safety reasons. At a median follow-up of
2 mo, death had occurred in 8.1% of the dronedarone
group and 3.8% of the placebo group.
95% CI: 1.07 to 4.25;
p0.03
HR: 2.13 Dronedarone increased
early mortality in patients
recently hospitalized with
symptomatic HF and
depressed LV function.
96% of deaths were
attributed to CV causes,
predominantly
progressive HF and
arrhythmias.
After an additional 6 mo, 42 patients in the dronedarone
group (13.5%) and 39 patients in the placebo group
(12.3%) died.
95% CI: 0.73 to 1.74;
p0.60
HR: 1.13
The primary endpoint did not differ significantly between
the 2 groups; there were 53 events in the dronedarone
group (17.1%) and 40 events in the placebo group
(12.6%).
95% CI: 0.92 to 2.09;
p0.12
HR: 1.38
ATHENA,
Hohnloser et al.
(29)
To determine if
dronedarone would
reduce rate of composite
outcome of
hospitalization due to CV
events or death in
patients with AF.
4,628 Inclusion criteria: Patients with paroxysmal or persistent
AF or atrial flutter with at least 1 of the following: age at
least 70 y, arterial HTN, DM, previous stroke, TIA,
systemic embolism, LA diameter 50 mm, and LVEF
40%.
Exclusion criteria: Permanent AF; unstable hemodynamic
condition (ie, decompensated HF within previous 4 wk);
NYHA class IV CHF; planned major surgery; acute
myocarditis; bradycardia with a heart rate of 50 bpm
or PR interval 0.28 s or previous clinically significant
sinus-node disease; severe noncardiac illness limiting
life expectancy; pregnancy, breast-feeding, or lack of
adequate birth control among women of childbearing
potential; calculated glomerular filtration rate at baseline
10 mL/min, potassium level 3.5 mmol/L if not
currently being corrected, and requirement for
concomitant medication that was prohibited.
Primary outcome was death or
first hospitalization due to CV
events. Secondary outcomes were
death from any cause, death from
CV causes, and hospitalization
due to CV events.
Primary outcome occurred in 734 patients (31.9%) in
the dronedarone group and in 917 patients (39.4%) in
the placebo group.
95% CI: 0.69 to 0.84;
p0.001
HR: 0.76 Dronedarone reduced
risk of hospitalization or
death in patients with
paroxysmal or persistent
AF or atrial flutter, which
was largely due to a
reduction in
hospitalization for AF.
Death from any cause
was not reduced.
Adverse effects that were
more common with
dronedarone than
placebo were
bradycardia, prolonged
QT, diarrhea, nausea,
rash, and increase in
serum creatinine.
116 deaths (5%) in the dronedarone group and 139
(6%) in the placebo group.
95% CI: 0.66 to 1.08;
p0.18
HR: 0.84
63 deaths from CV causes (2.7%) in the dronedarone
group and 90 (3.9%) in the placebo group.
95% CI: 0.51 to 0.98;
p0.03
HR: 0.71
675 (29.3%) first hospitalizations due to CV events in
the dronedarone group and 859 (36.9%) in the placebo
group. A first hospitalization for AF occurred in 14.6% of
the dronedarone group and 21.9% of the placebo group.
95% CI: 0.67 to 0.82;
p0.001
HR: 0.74
26 (1.1%) deaths from cardiac arrhythmia in the
dronedarone group and 48 (2.1%) in the placebo group.
95% CI: 0.34 to 0.88;
p0.01
HR: 0.55
Analysis of
stroke in
ATHENA,
Connolly et al.
(37)
To assess efficacy of
dronedarone 400 mg bid
for prevention of CV
hospitalization or death
from any cause in
patients with AF/atrial
flutter.
4,628 Inclusion criteria: Paroxysmal or persistent AF or atrial
flutter and at least 1 additional risk factor for CV events,
including age 75 y or age 70 y with 1 of the
following: HTN, DM, prior stroke or TIA, LA enlargement
(50 mm Hg), or depressed LVEF (40%).
Exclusion criteria: Permanent AF, unstable hemodynamic
situation, and NYHA class IV HF. Patients must have had
both SR and AF or atrial flutter documented in 6 mo
before enrollment.
Primary endpoint was first
occurrence of CV hospitalization
or death due to any cause.
Analysis of stroke posthoc and not
prespecified.
Risk of stroke decreased from 1.8% per year to 1.2%
per year.
95% CI: 0.46 to 0.96;
p0.027
HR: 0.66 Fewer strokes occurred
in the dronedarone
group, but this finding
was not anticipated and
was not prespecified.
Whether it was a chance
finding or due to a
beneficial effect of the
drug is not certain.
(Continued)
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DAFNE,
Touboul et al.
(33)
To determine most
appropriate dose of
dronedarone for
prevention of AF after
cardioversion.
474 Inclusion criteria: Either sex, age 21–85 y, with
persistent AF (72-h and 12-mo duration) in which
cardioversion and antiarrhythmic treatment are
warranted. AF either lone or associated with ischemic or
hypertensive heart disease or DCM.
Exclusion criteria: More than 2 cardioversions in last 6
mo, acute reversible cause; atrial flutter as presenting
arrhythmia; unstable angina or recent MI; QT interval
500 ms or history of torsades de pointes; severe
bradycardia; advanced AVB; treatment with other
antiarrhythmic drugs, NYHA class III or IV CHF; LVEF
35%; Wolff-Parkinson-White syndrome; ICD.
Primary endpoint was time to first
documented AF recurrence (AF
defined as episode lasting for at
least 10 min and documented by
2 distinct ECGs separated by
same time duration).
Increased time to AF relapse with 800 mg of
dronedarone (effect less apparent at higher doses).
Median time to first AF recurrence was 5.3 d in placebo
group and at 60 d in the 800-mg dronedarone group. At
6 mo 35% of patients treated with 800-mg dronedarone
remained in SR versus 10% of placebo group.
95% CI: 28 to 72;
p0.001
RR reduction: 55% Dronedarone 800 mg qd
appeared to be safe and
effective for prevention of
AF relapses after
cardioversion.
DIONYSOS,
Le Heuzey
et al. (36)
To compare efficacy and
safety of amiodarone and
dronedarone in patients
with persistent AF.
504 (249
dronedarone 400 mg
bid; 255 amiodarone
600 mg qd for 28 d,
then 200 mg qd).
Inclusion criteria: Age 21 y, documented AF for 72
h in patients for whom cardioversion and antiarrhythmic
treatment were indicated and who were receiving oral
anticoagulants.
Exclusion criteria: Previous chronic treatment with
amiodarone, hypo- or hyperthyroidism or other
contraindications to amiodarone, corrected QT interval
500 ms, paroxysmal AF, atrial flutter, severe NYHA
class III or IV CHF, severe bradycardia, or high-degree
AVB. Patients in whom contraindicated concomitant
treatment was mandatory were excluded (including
Vaughan Williams Class I and III antiarrhythmic drugs;
drugs that cause torsades de pointes; potent inhibitors
of cytochrome P[CYP] 3A4; and substrates of CYP3A4
with narrow therapeutic margin).
Primary composite endpoint was
recurrence of AF (including
unsuccessful electrical
cardioversion, no spontaneous
conversion, and no electrical
cardioversion) or premature
discontinuation of study. MSE was
occurrence of thyroid, hepatic,
pulmonary, neurologic,
dermatologic, ocular, or
gastrointestinal-specific events or
premature discontinuation of study
drug after adverse event.
Dronedarone 75.1%; amiodarone 58.8%
AF recurrence after successful cardioversion: 36.5% with
dronedarone and 24.3% with amiodarone.
Premature discontinuation of drug tended to be less
frequent with dronedarone (10.4% versus 13.3%).
95% CI: 1.28 to 1.98;
p0.0001
HR: 1.59 Dronedarone was less
effective than
amiodarone in
decreasing AF
recurrence; however, it
had a better safety
profile.
MSE was 39.3% with dronedarone and 44.5% with
amiodarone at 12 mo, mainly driven by fewer thyroid,
neurologic, dermatologic, and ocular events in
dronedarone group.
95% CI: 0.60 to 1.07;
p0.129
HR: 0.80
EURIDIS,
Singh et al.
(32)
To evaluate dronedarone
compared with placebo
for maintenance of SR
after electrical,
pharmacologic, or
spontaneous conversion
from AF or atrial flutter
612 Inclusion criteria: Either sex, age at least 21 y, and at
least 1 episode of AF (as seen on ECG) in preceding 3
mo and in SR for at least 1 h before randomization.
Exclusion criteria: Patients with permanent AF (ie,
duration of at least 12 mo); women who could become
pregnant and who were not using birth control; patients
who had torsades de pointes; patients with persistent
bradycardia of 50 bpm, a PR interval of 0.28 on
ECG, second-degree (or higher) AVB, and clinically
significant sinus-node disease without an implanted
pacemaker; patients taking Class I or III antiarrhythmic
agents; patients with NYHA class III or IV CHF; and
patients with serum creatinine level 1.7 mg/dL (150
mol/L), severe electrolyte abnormalities, and clinically
significant hepatic, pulmonary, endocrine, or other
disorders associated with AF.
Primary endpoint was time from
randomization to first documented
recurrence of AF. Secondary
endpoints were symptoms and
mean ventricular rate during first
AF recurrence.
Median times from randomization to documentated
recurrence of AF were 96 d in dronedarone group and
41 d in placebo group.
At 12 mo 67.1% of patients in dronedarone group and
77.5% of placebo group had recurrence of AF.
95% CI: 0.64 to 0.96;
p0.01
HR: 0.78 Dronedarone was
significantly more
effective than placebo in
maintaining SR.
(Continued)
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RACE II,
Van Gelder
et al. (3)
To investigate if lenient
rate control is not inferior
to strict control for
preventing CV morbidity
and mortality in patients
with permanent AF.
614 Inclusion criteria: Permanent AF up to 12 mo, age 80
y, mean resting heart rate 80 bpm, and current use of
oral anticoagulation therapy (or ASA if no risk factors for
thromboembolic complications present).
Exclusion Criteria: Paroxysmal AF; contraindications for
either strict or lenient rate control (eg, previous adverse
effects on negative chronotrophic drugs); unstable HF
defined as NYHA class IV HF or HF necessitating hospital
admission 3 mo before inclusion; cardiac surgery 3
mo ago; any stroke; current or foreseen pacemaker,
ICD, and/or cardiac resynchronization therapy; signs of
sick sinus syndrome or AV conduction disturbances (ie,
symptomatic bradycardia or asystole 3 s or escape
rate 40 bpm in awake symptom-free patients;
untreated hyperthyroidism or 3 mo euthyroidism;
inability to walk or ride a bike.
Composite of death from CV
causes, hospitalization for HF, and
stroke, systemic embolism,
bleeding, and life-threatening
arrhythmic events. Follow-up
duration 2 y, with maximum 3 y.
Primary outcome incidence at 3 y was 12.9% in lenient-
control group and 14.9% in strict-control group. Absolute
difference with respect to lenient-control group of
2.0%.
90% CI: 0.58 to 1.21;
p0.001
HR: 0.84 Lenient rate control is as
effective as strict rate
control and easier to
achieve in patients with
permanent AF.
Absolute difference
2.0%
Absolute difference,
90% CI: 7.6 to 3.5;
p0.001
More patients in lenient-control group met heart rate
target or targets (304 [97.7%] versus 203 [67.0%] in
strict-control group).
Frequencies of symptoms and adverse events were
similar in the 2 groups.
p0.001
ThermoCool,
Wilber et al.
(51)
To investigate catheter
ablation with ADT in
patients with
symptomatic AF.
167 Inclusion criteria: Enrollment required at least 3 episodes
of symptomatic AF (1 episode verified by ECG) within
6 mo before randomization and not responding to at
least 1 antiarrhythmic drug (class I, class III, or AV nodal
blocker).
Exclusion criteria: AF 30 d, 18 y, EF 40%,
previous ablation for AF, documented LA thrombus,
amiodarone therapy in previous 6 mo, NYHA class III or
IV, MI within previous 2 mo, CABG within previous 12
mo, thromboembolic event in previous 12 mo, severe
pulmonary disease, prior valvular cardiac surgical
procedure, presence of ICD, contraindication to
antiarrhythmic or anticoagulation medications, life
expectancy 12 mo, and LA size of at least 50 mm in
parasternal long axis.
Primary endpoint was freedom
from protocol-defined treatment
failure, which included
documented symptomatic
paroxysmal AF during
effectiveness evaluation period.
66% of patients in catheter ablation group remained free
from protocol-defined treatment failure versus 16% of
patients treated with ADT.
95% CI: 0.19 to 0.47;
p0.001
HR: 0.30 Catheter ablation is more
effective than medical
therapy alone in
preventing recurrent
symptoms of paroxysmal
AF in patients who have
already failed treatment
with 1 antiarrhythmic
drug. Ideal candidates for
catheter ablation are
younger patients with
minimal structural
abnormalities and
multiple symptomatic
episodes of paroxysmal
AF over time despite
appropriate
pharmacological therapy.
70% of patients treated by catheter ablation remained
free of symptomatic recurrent atrial arrhythmia versus
19% of patients treated with ADT.
95% CI: 0.15 to 0.39;
p0.001
HR: 0.24
63% of patients treated by catheter ablation were free
of recurrent atrial arrhythmia versus 17% of patients
treated with ADT.
95% CI: 0.18 to 0.45;
p0.001
HR: 0.29
ADT indicates antiarrhythmic drug therapy; AF, atrial fibrillation; ASA, aspirin; AV, atrioventricular; AVB, atrioventricular block; bid, twice a day; bpm, beats per minute; CABG, coronary artery bypass graft surgery; CAD, coronary
artery disease; CHF, congestive heart failure; CI: confidence interval; CNS, central nervous system; CYP, cytochrome P; CV, cardiovascular; d, day; DCM, dilated cardiomyopathy; DM, diabetes mellitus; ECG, electrocardiogram;
EF, ejection fraction; h, hour; HF, heart failure; HR, hazard ratio; HTN, hypertension; ICD, implantable cardioverter-defibrillator; IV, intravenous; LA, left atrial; LBBB, left bundle-branch block; LV, left ventricular; LVEF, left ventricular
ejection fraction; MI, myocardial infarction; mm, millimeter; mo, month; ms, milliseconds; MSE, main safety endpoint; NYHA, New York Heart Association; PAD, peripheral arterial disease; PR interval, interval between onset of
P wave and onset of QRS complex on an ECG; PVD, peripheral vascular disease; qd, once per day; RR, relative risk; s, seconds; SD, standard deviation; SOB, short of breath; SR, sinus rhythm; TIA, transient ischemic attack;
wk, week; and y, year.
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